Creo Medical Group PLC Director/PDMR Shareholding (2870I)

TIDMCREO

RNS Number : 2870I

Creo Medical Group PLC

07 August 2019

Creo Medical Group plc

("Creo" or the "Company")

Director / PDMR Shareholding

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that on 6 August 2019, Charles Spicer, Non-Executive Chairman, purchased 14,220 ordinary shares of GBP0.001 each in the capital of the Company ("Ordinary Shares") via his Self-Invested Personal Pension ("SIPP") at a price of 140.64 pence per Ordinary Share.

Following this purchase, Charles Spicer holds 80,010 Ordinary Shares in the Company, representing approximately 0.066% of the Company's issued share capital.

The information below, set out in accordance with the requirements of the MAR, provides further detail.

 
    1        Details of the person discharging managerial responsibilities 
              / person closely associated 
    a)       Name                                 Charles Spicer 
         --------------------------------------  --------------------------------------- 
    2        Reason for the notification 
         ------------------------------------------------------------------------------- 
    a)       Position/status                      Non-Executive Chairman 
         --------------------------------------  --------------------------------------- 
    b)       Initial notification                 Initial notification 
              /Amendment 
         --------------------------------------  --------------------------------------- 
    3        Details of the issuer, emission allowance market participant, 
              auction platform, auctioneer or auction monitor 
         ------------------------------------------------------------------------------- 
    a)       Name                                 Creo Medical Group plc 
         --------------------------------------  --------------------------------------- 
    b)       LEI                                  213800H188ZDCWWXFA21 
         --------------------------------------  --------------------------------------- 
    4     Details of the transaction(s): section to be repeated for 
           (i) each type of instrument; (ii) each type of transaction; 
           (iii) each date; and (iv) each place where transactions have 
           been conducted 
         ------------------------------------------------------------------------------- 
    a)       Description of the                   Ordinary shares of GBP0.001 each 
              financial instrument, 
              type of instrument 
 
             Identification code                  GB00BZ1BLL44 
 
    b)       Nature of the transaction            Purchase of shares via SIPP 
         --------------------------------------  --------------------------------------- 
    c)       Price(s) and volume(s) 
                                                  --------------------  -------------- 
                                                   Price(s)              Volume(s) 
                                                  --------------------  -------------- 
    140.64 pence                                                         14,220 
   -------------------------------------------------------------------  -------------- 
 
    d)       Aggregated information 
 
     - Aggregated volume                  N/A - single transaction 
 
     - Price 
 
    e)       Date of the transaction              6 August 2019 
         --------------------------------------  --------------------------------------- 
    f)       Place of the transaction             London Stock Exchange 
         --------------------------------------  --------------------------------------- 
 
 
    Creo Medical Group plc 
    Richard Rees (CFO)                                                       [phone] 
 
    Cenkos Securities                                                        [phone] 
    Stephen Keys / Mark Connelly (NOMAD) 
    Michael Johnson / Russell Kerr (Sales) 
 
    Walbrook PR Ltd                              Tel: [phone] or [e-mail] 
    Paul McManus                                                        Mob: [phone] 
    Lianne Cawthorne                                                    Mob: [phone] 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHLLFEFTEIDIIA

(END) Dow Jones Newswires

August 07, 2019 08:57 ET (12:57 GMT)